Menarini And Radius Skip Into SERD Lead With Elacestrant Success

Breast Cancer Therapy Improves PFS In Phase III EMERALD Trial

Elacestrant has become the first oral SERD to generate positive topline results in a pivotal study as a monotherapy versus standard of care for ER+/HER2- advanced or metastatic breast cancer.

emerald
Elacestrant sparkles in emerald • Source: Alamy

While a number of oral SERD (selective estrogen receptor degrader) breast cancer drugs are moving closer to the market, Menarini Groupand partner Radius Health, Inc. have moved ahead of the pack with promising late-stage data for elacestrant.

The partners have announced positive topline progression-free survival (PFS) results from the Phase III EMERALD trial for elacestrant, their SERD...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.